Literature DB >> 23699602

Oxidized low-density lipoproteins induce rapid platelet activation and shape change through tyrosine kinase and Rho kinase-signaling pathways.

Katie S Wraith1, Simbarashe Magwenzi, Ahmed Aburima, Yichuan Wen, David Leake, Khalid M Naseem.   

Abstract

Oxidized low-density lipoproteins (oxLDL) generated in the hyperlipidemic state may contribute to unregulated platelet activation during thrombosis. Although the ability of oxLDL to activate platelets is established, the underlying signaling mechanisms remain obscure. We show that oxLDL stimulate platelet activation through phosphorylation of the regulatory light chains of the contractile protein myosin IIa (MLC). oxLDL, but not native LDL, induced shape change, spreading, and phosphorylation of MLC (serine 19) through a pathway that was ablated under conditions that blocked CD36 ligation or inhibited Src kinases, suggesting a tyrosine kinase-dependent mechanism. Consistent with this, oxLDL induced tyrosine phosphorylation of a number of proteins including Syk and phospholipase C γ2. Inhibition of Syk, Ca(2+) mobilization, and MLC kinase (MLCK) only partially inhibited MLC phosphorylation, suggesting the presence of a second pathway. oxLDL activated RhoA and RhoA kinase (ROCK) to induce inhibitory phosphorylation of MLC phosphatase (MLCP). Moreover, inhibition of Src kinases prevented the activation of RhoA and ROCK, indicating that oxLDL regulates contractile signaling through a tyrosine kinase-dependent pathway that induces MLC phosphorylation through the dual activation of MLCK and inhibition of MLCP. These data reveal new signaling events downstream of CD36 that are critical in promoting platelet aggregation by oxLDL.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23699602      PMCID: PMC3724193          DOI: 10.1182/blood-2013-04-491688

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  The involvement of Ca2+ and myosin light chain kinase in collagen-induced platelet activation.

Authors:  V B Lokeshwar; L Y Bourguignon
Journal:  Cell Biol Int Rep       Date:  1992-09

2.  Signaling role of CD36 in platelet activation and thrombus formation on immobilized thrombospondin or oxidized low-density lipoprotein.

Authors:  R Nergiz-Unal; M M E Lamers; R Van Kruchten; J J Luiken; J M E M Cosemans; J F C Glatz; M J E Kuijpers; J W M Heemskerk
Journal:  J Thromb Haemost       Date:  2011-09       Impact factor: 5.824

3.  Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase.

Authors:  Shideh Kazerounian; Mark Duquette; Millys A Reyes; James T Lawler; Keli Song; Carole Perruzzi; Luca Primo; Roya Khosravi-Far; Federico Bussolino; Isaac Rabinovitz; Jack Lawler
Journal:  Blood       Date:  2011-03-04       Impact factor: 22.113

Review 4.  Molecular mechanisms of platelet activation.

Authors:  W Siess
Journal:  Physiol Rev       Date:  1989-01       Impact factor: 37.312

Review 5.  Sulfo-N-succinimidyl esters of long chain fatty acids specifically inhibit fatty acid translocase (FAT/CD36)-mediated cellular fatty acid uptake.

Authors:  Susan L M Coort; Jodil Willems; Will A Coumans; Ger J van der Vusse; Arend Bonen; Jan F C Glatz; Joost J F P Luiken
Journal:  Mol Cell Biochem       Date:  2002-10       Impact factor: 3.396

6.  Reversible phosphorylation of smooth muscle myosin, heavy meromyosin, and platelet myosin.

Authors:  J R Sellers; M D Pato; R S Adelstein
Journal:  J Biol Chem       Date:  1981-12-25       Impact factor: 5.157

7.  LDLs increase the exposure of fibrinogen binding sites on platelets and secretion of dense granules.

Authors:  G van Willigen; G Gorter; J W Akkerman
Journal:  Arterioscler Thromb       Date:  1994-01

8.  Regulation of human platelet myosin light chain kinase by the catalytic subunit of cyclic AMP-dependent protein kinase.

Authors:  D R Hathaway; C R Eaton; R S Adelstein
Journal:  Nature       Date:  1981-05-21       Impact factor: 49.962

9.  Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets.

Authors:  M M Huang; J B Bolen; J W Barnwell; S J Shattil; J S Brugge
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

10.  Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype.

Authors:  Eugene A Podrez; Tatiana V Byzova; Maria Febbraio; Robert G Salomon; Yi Ma; Manojkumar Valiyaveettil; Eugenia Poliakov; Mingjiang Sun; Paula J Finton; Brian R Curtis; Juhua Chen; Renliang Zhang; Roy L Silverstein; Stanley L Hazen
Journal:  Nat Med       Date:  2007-08-26       Impact factor: 53.440

View more
  28 in total

1.  CD36: linking lipids to the NLRP3 inflammasome, atherogenesis and atherothrombosis.

Authors:  Cécile Oury
Journal:  Cell Mol Immunol       Date:  2013-10-07       Impact factor: 11.530

2.  Oxidized LDL signals through Rho-GTPase to induce endothelial cell stiffening and promote capillary formation.

Authors:  Myung-Jin Oh; Chongxu Zhang; Elizabeth LeMaster; Crystal Adamos; Evgeny Berdyshev; Yedida Bogachkov; Erin E Kohler; Jugajyoti Baruah; Yun Fang; Dean E Schraufnagel; Kishore K Wary; Irena Levitan
Journal:  J Lipid Res       Date:  2016-03-17       Impact factor: 5.922

3.  SYK regulates macrophage MHC-II expression via activation of autophagy in response to oxidized LDL.

Authors:  Soo-Ho Choi; Ayelet Gonen; Cody J Diehl; Jungsu Kim; Felicidad Almazan; Joseph L Witztum; Yury I Miller
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

4.  Platelet CD36 promotes thrombosis by activating redox sensor ERK5 in hyperlipidemic conditions.

Authors:  Moua Yang; Brian C Cooley; Wei Li; Yiliang Chen; Jeannette Vasquez-Vivar; Na'il O Scoggins; Scott J Cameron; Craig N Morrell; Roy L Silverstein
Journal:  Blood       Date:  2017-03-23       Impact factor: 22.113

5.  Serum-borne bioactivity caused by pulmonary multiwalled carbon nanotubes induces neuroinflammation via blood-brain barrier impairment.

Authors:  Mario J Aragon; Lauren Topper; Christina R Tyler; Bethany Sanchez; Katherine Zychowski; Tamara Young; Guy Herbert; Pamela Hall; Aaron Erdely; Tracy Eye; Lindsey Bishop; Samantha A Saunders; Pretal P Muldoon; Andrew K Ottens; Matthew J Campen
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

Review 6.  Platelets and cancer: a casual or causal relationship: revisited.

Authors:  David G Menter; Stephanie C Tucker; Scott Kopetz; Anil K Sood; John D Crissman; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2014-03       Impact factor: 9.264

7.  Platelet CD36 signaling through ERK5 promotes caspase-dependent procoagulant activity and fibrin deposition in vivo.

Authors:  Moua Yang; Andaleb Kholmukhamedov; Marie L Schulte; Brian C Cooley; Na'il O Scoggins; Jeremy P Wood; Scott J Cameron; Craig N Morrell; Shawn M Jobe; Roy L Silverstein
Journal:  Blood Adv       Date:  2018-11-13

Review 8.  The Evidence for Saturated Fat and for Sugar Related to Coronary Heart Disease.

Authors:  James J DiNicolantonio; Sean C Lucan; James H O'Keefe
Journal:  Prog Cardiovasc Dis       Date:  2015-11-14       Impact factor: 8.194

9.  Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade.

Authors:  Simbarashe Magwenzi; Casey Woodward; Katie S Wraith; Ahmed Aburima; Zaher Raslan; Huw Jones; Catriona McNeil; Stephen Wheatcroft; Nadira Yuldasheva; Maria Febbriao; Mark Kearney; Khalid M Naseem
Journal:  Blood       Date:  2015-02-20       Impact factor: 22.113

Review 10.  CD36 and ERK5 link dyslipidemia to apoptotic-like platelet procoagulant function.

Authors:  Moua Yang; Roy L Silverstein
Journal:  Curr Opin Hematol       Date:  2019-09       Impact factor: 3.218

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.